Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vimian Group AB is a Sweden-based global animal health company specializing in four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company unites leading businesses in animal health niches with unmet needs and strong growth potential, combining forward-leaning R&D initiatives to deliver innovative products, services, and treatments to veterinary professionals, labs, and pet owners worldwide. Operating across 80 markets with approximately 1,200 employees and generating 375 million euros in revenues, Vimian Group AB emphasizes science, technology, and customer needs to enhance animal care. Notable features include global distribution networks, professional training programs, and a focus on sustainability through ESG initiatives centered on people, animals, and the planet. Headquartered in Stockholm, the company supports entrepreneurial partners by providing expertise, infrastructure, and capital to accelerate innovation and market expansion in the veterinary sector.
kr 2.67
+kr 0.01 (+0.56%)
EOD Jun 26, 2026 · Twelve Data
15.91% operating margin is respectable but not wide. ROIC at 5.06%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 13.4% YoY with margins expanding 2.7pp.
Even for strong businesses, today's 3x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
3.4x earnings, 1.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€434M
▲ +13.4% YoY
Net Income (TTM)
€38M
▲ +67.4% YoY
Op. Margin
16.86%
▲ +2.7pp YoY
ROIC
5.06%
▲ +1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€93M
▲ +106.4% YoY
Op. Cash Flow (TTM)
€105M
▲ +80.1% YoY
Net Debt
€184M
Cash & Equiv.
€55M
3Y CAGR: +14.7%
3Y CAGR: +82.1%
Continue Research
At a P/E of 3.4 and a price-to-free-cash-flow of 1.4, Vimian Group AB (VIMIAN.XSTO) trades below a two-stage DCF intrinsic value of about €8.51 per share, so at €2.68 the stock looks undervalued (218.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vimian Group AB scores 70/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €8.51 per share for VIMIAN.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €6.38. At today's €2.68, that puts the stock about 218.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Vimian Group AB scores 70 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 16.9% operating margin and a 5.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. VIMIAN.XSTO currently trades below its estimated intrinsic value and scores 70/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.